Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to "Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure".
Lanier M, Pickens J, Bigi SV, Bradshaw-Pierce EL, Chambers A, Cheruvallath ZS, Cole D, Dougan DR, Ermolieff J, Gibson T, Halkowycz P, Hirokawa A, Ivetac A, McBride C, Miura J, Nunez E, Sabat M, Tyhonas J, Wang H, Wang X, Swann S. Lanier M, et al. Among authors: miura j. ACS Med Chem Lett. 2017 Nov 8;8(12):1341. doi: 10.1021/acsmedchemlett.7b00457. eCollection 2017 Dec 14. ACS Med Chem Lett. 2017. PMID: 29259759 Free PMC article.
Design, synthesis and SAR of novel glucokinase activators.
Cheruvallath ZS, Gwaltney SL 2nd, Sabat M, Tang M, Feng J, Wang H, Miura J, Guntupalli P, Jennings A, Hosfield D, Lee B, Wu Y. Cheruvallath ZS, et al. Among authors: miura j. Bioorg Med Chem Lett. 2013 Apr 1;23(7):2166-71. doi: 10.1016/j.bmcl.2013.01.093. Epub 2013 Feb 4. Bioorg Med Chem Lett. 2013. PMID: 23434031
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.
Cheruvallath Z, Tang M, McBride C, Komandla M, Miura J, Ton-Nu T, Erikson P, Feng J, Farrell P, Lawson JD, Vanderpool D, Wu Y, Dougan DR, Plonowski A, Holub C, Larson C. Cheruvallath Z, et al. Among authors: miura j. Bioorg Med Chem Lett. 2016 Jun 15;26(12):2774-2778. doi: 10.1016/j.bmcl.2016.04.073. Epub 2016 Apr 25. Bioorg Med Chem Lett. 2016. PMID: 27155900
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.
Lanier M, Pickens J, Bigi SV, Bradshaw-Pierce EL, Chambers A, Cheruvallath ZS, Cole D, Dougan DR, Ermolieff J, Gibson T, Halkowycz P, Hirokawa A, Ivetac A, Miura J, Nunez E, Sabat M, Tyhonas J, Wang H, Wang X, Swann S. Lanier M, et al. Among authors: miura j. ACS Med Chem Lett. 2017 Feb 8;8(3):316-320. doi: 10.1021/acsmedchemlett.6b00481. eCollection 2017 Mar 9. ACS Med Chem Lett. 2017. PMID: 28337323 Free PMC article.
The discovery of (1R, 3R)-1-(3-chloro-5-fluorophenyl)-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile, a potent and selective agonist of human transient receptor potential cation channel subfamily m member 5 (TRPM5) and evaluation of as a potential gastrointestinal prokinetic agent.
Sabat M, Raveglia LF, Aldegheri L, Barilli A, Bianchi F, Brault L, Brodbeck D, Feriani A, Lingard I, Miura J, Myers R, Piccoli L, Tassini S, Tyhonas J, Ton-Nu T, Wang H, Virginio C. Sabat M, et al. Among authors: miura j. Bioorg Med Chem. 2022 Dec 15;76:117084. doi: 10.1016/j.bmc.2022.117084. Epub 2022 Nov 6. Bioorg Med Chem. 2022. PMID: 36402081
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A, Jones B, Matuszkiewicz J, Miura J, Miyake H, Natala SR, Shi L, Takahashi M, Taylor E, Wyrick C, Yano J, Zalevsky J, Nie Z. Lam B, et al. Among authors: miura j. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950. doi: 10.1016/j.bmcl.2016.10.087. Epub 2016 Nov 2. Bioorg Med Chem Lett. 2016. PMID: 27839918
Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1.
Sabat M, Carney DW, Hernandez-Torres G, Gibson TS, Balakrishna D, Zou H, Xu R, Chen CH, de Jong R, Dougan DR, Qin L, Bigi-Botterill SV, Chambers A, Miura J, Johnson LK, Ermolieff J, Johns D, Selimkhanov J, Kwok L, DeMent K, Proffitt C, Vu P, Lindsey EA, Ivetac T, Jennings A, Wang H, Manam P, Santos C, Fullenwider C, Manohar R, Flick AC. Sabat M, et al. Among authors: miura j. J Med Chem. 2024 Jun 13. doi: 10.1021/acs.jmedchem.4c00743. Online ahead of print. J Med Chem. 2024. PMID: 38872300
Outcomes of Merkel Cell Carcinoma in the Era of Immune Checkpoint Blockade.
Shafique N, Dheer A, Tortorello G, Chu EY, Ming ME, Miura JT, Karakousis GC. Shafique N, et al. Among authors: miura jt. Ann Surg Oncol. 2024 Jun 10. doi: 10.1245/s10434-024-15558-5. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38858292 No abstract available.
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
Shigeta N, Murakami S, Yokose T, Isaka T, Shinada K, Nagashima T, Adachi H, Shigefuku S, Murakami K, Miura J, Kikunishi N, Watabe K, Saito H, Ito H. Shigeta N, et al. Among authors: miura j. Thorac Cancer. 2024 Jun;15(17):1343-1349. doi: 10.1111/1759-7714.15319. Epub 2024 May 3. Thorac Cancer. 2024. PMID: 38698758 Free PMC article.
370 results